INTRODUCTION: Low grade gliomas are the commonest brain tumours in children but present in a myriad of ways, each with its own treatment challenges. Conventional MRI scans play an important role in their management but have limited ability to identify likely clinical behaviour. The aim of this study is to investigate (1)H magnetic resonance spectroscopy (MRS) as a method for detecting differences between the various low grade gliomas and related tumours in children. PATIENTS AND METHODS: Short echo time single voxel (1)H MRS at 1.5 or 3.0 T was performed prior to treatment on children with low grade brain tumours at two centres and five MR scanners, 69 cases had data which passed quality control. MRS data was processed using LCModel to give mean spectra and metabolite concentrations which were compared using T-tests, ANOVA, Receiver Operator Characteristic curves and logistic regression in SPSS. RESULTS: Significant differences were found in concentrations of key metabolites between glioneuronal and glial tumours (T-test p<0.05) and between most of the individual histological subtypes of low grade gliomas. The discriminatory metabolites identified, such as choline and myoinositol, are known tumour biomarkers. In the set of pilocytic astrocytomas and unbiopsied optic pathway gliomas, significant differences (p<0.05, ANOVA) were found in metabolite profiles of tumours depending on location and patient neurofibromatosis type 1 status. Logistic regression analyses yielded equations which could be used to assess the probability of a tumour being of a specific type. CONCLUSIONS: MRS can detect subtle differences between low grade brain tumours in children and should form part of the clinical assessment of these tumours.
INTRODUCTION: Low grade gliomas are the commonest brain tumours in children but present in a myriad of ways, each with its own treatment challenges. Conventional MRI scans play an important role in their management but have limited ability to identify likely clinical behaviour. The aim of this study is to investigate (1)H magnetic resonance spectroscopy (MRS) as a method for detecting differences between the various low grade gliomas and related tumours in children. PATIENTS AND METHODS: Short echo time single voxel (1)H MRS at 1.5 or 3.0 T was performed prior to treatment on children with low grade brain tumours at two centres and five MR scanners, 69 cases had data which passed quality control. MRS data was processed using LCModel to give mean spectra and metabolite concentrations which were compared using T-tests, ANOVA, Receiver Operator Characteristic curves and logistic regression in SPSS. RESULTS: Significant differences were found in concentrations of key metabolites between glioneuronal and glial tumours (T-test p<0.05) and between most of the individual histological subtypes of low grade gliomas. The discriminatory metabolites identified, such as choline and myoinositol, are known tumour biomarkers. In the set of pilocytic astrocytomas and unbiopsied optic pathway gliomas, significant differences (p<0.05, ANOVA) were found in metabolite profiles of tumours depending on location and patient neurofibromatosis type 1 status. Logistic regression analyses yielded equations which could be used to assess the probability of a tumour being of a specific type. CONCLUSIONS: MRS can detect subtle differences between low grade brain tumours in children and should form part of the clinical assessment of these tumours.
Authors: T Jaspan; P S Morgan; M Warmuth-Metz; E Sanchez Aliaga; D Warren; R Calmon; J Grill; D Hargrave; J Garcia; G Zahlmann Journal: AJNR Am J Neuroradiol Date: 2016-04-28 Impact factor: 3.825
Authors: Karen A Manias; Simrandip K Gill; Lesley MacPherson; Adam Oates; Benjamin Pinkey; Paul Davies; Niloufar Zarinabad; Nigel P Davies; Ben Babourina-Brooks; Martin Wilson; Andrew C Peet Journal: Neurooncol Pract Date: 2019-05-09
Authors: Simrandip K Gill; Martin Wilson; Nigel P Davies; Lesley MacPherson; Martin English; Theodoros N Arvanitis; Andrew C Peet Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: Sarah Kohe; Marie-Anne Brundler; Helen Jenkinson; Manoj Parulekar; Martin Wilson; Andrew C Peet; Carmel M McConville Journal: Br J Cancer Date: 2015-09-08 Impact factor: 7.640
Authors: Karen Manias; Simrandip K Gill; Niloufar Zarinabad; Paul Davies; Martin English; Daniel Ford; Lesley MacPherson; Ina Nicklaus-Wollenteit; Adam Oates; Guirish Solanki; Jenny Adamski; Martin Wilson; Andrew C Peet Journal: Neurooncol Pract Date: 2017-05-13
Authors: Eva-Maria Ratai; Zheng Zhang; James Fink; Mark Muzi; Lucy Hanna; Erin Greco; Todd Richards; Daniel Kim; Ovidiu C Andronesi; Akiva Mintz; Lale Kostakoglu; Melissa Prah; Benjamin Ellingson; Kathleen Schmainda; Gregory Sorensen; Daniel Barboriak; David Mankoff; Elizabeth R Gerstner Journal: PLoS One Date: 2018-06-14 Impact factor: 3.752
Authors: James T Grist; Jack J Miller; Fulvio Zaccagna; Mary A McLean; Frank Riemer; Tomasz Matys; Damian J Tyler; Christoffer Laustsen; Alasdair J Coles; Ferdia A Gallagher Journal: J Cereb Blood Flow Metab Date: 2020-03-10 Impact factor: 6.200